The Foundation for the National Institutes of Health (FNIH) and the Friends of Patients at the NIH (Friends) are launching a new collaboration called “Partnership for Patients” to leverage one another’s competence and infrastructure to ensure that patients in need at the NIH Clinical Center receive support to participate in groundbreaking and potentially life-saving treatments.
The Foundation for the National Institutes of Health (FNIH) has named the Doris Duke Charitable Foundation (DDCF) and Jane Sayer, Ph.D., the recipients of the 2019 Charles A. Sanders, M.D., Partnership Award. Now in its fourth year, this award recognizes persons and/or organizations that have made significant contributions to the FNIH’s work to build, implement and nurture public-private partnerships in support of the mission of the National Institutes of Health (NIH).
The Foundation for the National Institutes of Health (FNIH) has selected the finalists of the 2nd annual Trailblazer Prize for Clinician-Scientists (Trailblazer Prize): Ami S. Bhatt, M.D., Ph.D., Stanford University, James Kochenderfer, M.D., National Cancer Institute (NCI), Evan Macosko, M.D., Ph.D., Broad Institute and Giovanni Traverso, M.B., B.Chir, Ph.D., Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital, Harvard Medical School.
The Foundation for the National Institutes of Health (FNIH) is delighted to name Yasmine Belkaid, Ph.D., the winner of the 2019 Lurie Prize in Biomedical Sciences for blazing a trail in understanding the microbiome’s significant role in immune regulation. The human body houses trillions of microscopic organisms called microbes (i.e. bacteria, fungi and viruses) that collectively make up a microbiome. While many of these microbes are beneficial to health (commensal), others can be harmful (pathogenic). Dr. Belkaid revolutionized our understanding of the role of these microbes in the gut and skin, demonstrating that they are essential for triggering an immune response to help fight infection, but that they also can initiate inflammatory disease. The Lurie Prize in Biomedical Sciences will be presented to Dr. Belkaid at the FNIH Award Ceremony on May 22, 2019 in Washington, D.C.
The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the National Institutes of Health, is undergoing a major expansion to include patients with all non-small cell lung cancers – which make up about 85 percent of all lung cancer diagnoses in the U.S.
The Board of Directors of the Foundation for the National Institutes of Health (FNIH) welcomes distinguished scientific leader Elias Zerhouni, M.D., as its latest member. The FNIH Board of Directors elected Dr. Zerhouni in May 17, 2018 and his appointment takes effect on January 1, 2019.